

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Thomas BREVIG et al.

Appl. No.: NEW Group:

Filed: February 26, 2002 Examiner:

For: REDUCTION OF THE IMMUNOGENICITY OF NON-HUMAN GRAFTS

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents
Washington, DC 20231

February 26, 2002

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of the duty of disclosure under 37 C.F.R. § 1.56, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should have been forwarded from the International Search Authority pursuant to the trilateral agreement between the USPTO, EPO and JPO. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)a. **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

b. **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. **FOREIGN SEARCH REPORT OR ACTION**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A) (3).

d. **OTHER**

The following additional information is provided for the Examiner's consideration.

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON



Benoit Castel, Reg. No. 35,041

745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297

BC/bam

Enclosures: Form PTO-1449(s)
 Documents
 Foreign Search Report
 Other: _____

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Attorney Docket No.: 1501-1010	Application No.: NEW 069472
(Use several sheets if necessary)		Applicant: Thomas BREVIG et al.	
		Filing Date: February 26, 2002	Group Art Unit:

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Dialog Information Services, KOULMANDA et al., "FETAL PIG ISLET XENOGRAFTS IN NOD/LT MICE: THE EFFECT OF PERITRANSPLANT ANTI-CD4 MONOCLONAL ANTIBODY AND GRAFT IMMUNOMODIFICATION ON GRAFT SURVIVAL, AND LACK OF EXPRESSION OF GAL(1-3) GAL ON ENDOCRINE CELLS", 1995, pps. 295-305
		XP002922613, TINS, "THE IMMUNE RESPONSE TO INTRACEREBRAL NEURAL GRAFTS", Vol. 14, No. 8, 1991
		Journal Immunological Methods, NEETHLING et al., "A RELIABLE, RAPID AND INEXPENSIVE TWO-COLOR FLUORESCENCE ASSAY TO MONITOR SERUM CYTOTOXICITY IN XENOTRANSPLANTATION", pp. 31-44, 1998
		XP-000961820, ISACSON et al., "TRANSPLANTED XENOGENEIC NEURAL CELLS IN NEURODEGENERATIVE DISEASE MODELS EXHIBIT REMARKABLE AXONAL TARGET SPECIFICITY AND DISTINCT GROWTH PATTERNS OF GLIAL AND AXONAL FIBRES", pps. 1189-1194
		Dialog Information Services, FOX et al., "EVIDENCE THAT MACROPHAGES ARE REQUIRED FOR T-CELL INFILTRATION AND REJECTION OF FETAL PIG PANCREAS XENOGRAFTS IN NONOBES DIABETIC MICE", pps. 1407-1416, 1998
		XENOTRANSPLATATION, FRYER et al., "THE ROLE OF MONOCYTES AND MACROPHAGES IN DELAYED XENOGRAFT REJECTION", Vol. 4, pg. 40-48, 1997
		Eur. J. Neurosci. Suppl., BREVIG et al., "NEURAL XENOTRANSPLANTATION FOR BRAIN REPAIR: REDUCTION FOR PORCINE DONOR TISSUE IMMUNOGENICITY", pg. 294, 2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* Abstract provided for the Examiner's convenience